Diana Zuckerman, President of the National Research Center for Women & Families
November 19, 2010
Darvon is an opiate that has been on the market since the 1950’s and been controversial since the 1970’s. The FDA has been slow to require data ensuring its safety, and now finally has decided its risks outweigh its benefits. Darvon is a perfect example of the many drugs that have been used by millions of patients, despite inadequate proof that the benefits outweigh the risks. It is also a perfect example of how the FDA is now saving lives by reversing past approval decisions. Patients and consumers are benefiting from the FDA leadership’s stronger emphasis on improving public health.